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Jan H. Rüschoff1; Elise Gradhand, MD2; Abdullah Kahraman, PhD1; Helen Rees, MB, PhD3; Jane L. Ferguson, MBBS, MRCP, FRCR4;
Alessandra Curioni-Fontecedro, MD, PD1; Martin Zoche, PhD1; Holger Moch, MD1; and Bart Vrugt, MD, PhD1
INTRODUCTION
Malignant mesothelioma (MM) is a rare neoplasm
arising from the mesothelial cell lining of the pleura
(80% to 90%), but it can also develop in the peri-
toneum (10% to 15%), pericardium, and tunica
vaginalis.1,2 Because of the long latency of the disease,
the age at diagnosis ranges from 54 to 65 years3-5;
thus, MM rarely occurs in young patients and children.
The frequency of both pleural and peritoneal MM is
almost equal in patients younger than age 40 years. In
addition, previous asbestos exposure is less common
in peritoneal compared with pleural MM.6 Peritoneal
mesothelioma commonly presents with vague and
unspecific symptoms, including abdominal distension
and weight loss.7 Consequently, the diagnosis of peri-
toneal mesothelioma generally is made at an advanced
stage of the disease,8 which partly explains the poor
clinical outcome, even after optimal oncologic and
surgical treatment. The median survival is less than
12 months in the majority of patients.9,10 Patients with
MM are not routinely analyzed for the presence of
potentially drug-targetable gene mutations, including
anaplastic lymphoma tyrosine kinase (ALK). By using
targeted next-generation sequencing of tumor DNA and
RNA, Hung et al11 recently identified ALK rearrange-
ments with three novel ALK fusion partners in a small
subgroup of patients with peritoneal MM. Fusion part-
ners were ATG16L1, STRN, and TPM1. ATG16L1-ALK,
STRN-ALK, and TPM1-ALK fusions were all in-frame
alterations. The ALK breakpoint was mapped to intron
19 in all three cases, the STRN breakpoint to intron 3,
the ATG16L1 breakpoint to intron 2, and the TPMI1
breakpoint to the beginning of exon 9.
Here we report a 13-year-old girl with peritoneal me-
sothelioma harboring an STRN-ALK gene fusion,
which was identified by comprehensive genomic
profiling (CGP). The patient demonstrated a dramatic
response with marked clinical improvement after
treatment with ceritinib.
CASE REPORT
A 13-year-old previously healthy girl presented to her
general physician with a 4-month history of increasing
abdominal girth. She felt otherwise well, although her
appetite had reduced slightly, and she was attending
school as usual and continuing her sports activities. On
admission to the hospital, significant ascites was noted,
and a magnetic resonance imaging scan demonstrated
extensive peritoneal disease. Images before treat-
ment showed large-volume ascites, bilateral hydro-
nephrosis, and widespread peritoneal soft tissue
deposits particularly within the pelvis and around the
liver with scalloping of the liver margin (Fig 1). She
had no history of asbestos or radiation exposure.
Peritoneal biopsies were obtained by an explorative
laparoscopy and submitted for a histologic and mo-
lecular work-up.
PATHOLOGY
Multiple peritoneal biopsies revealed a tumor with
a mixed tubulopapillary and solid growth pattern.
Immunohistochemistry with positivity for CK5/6 and
calretinin in the absence of expression of the epithelial
marker BerEp-4 and claudin-4 confirmed the meso-
thelial origin of the tumor. Even though necrosis and
mitotic activity (less than 1 mitosis per 10 high-power
fields) were not evident, growth pattern, cytonuclear
atypia of the tumor cells, and immune profile fulfilled
the criteria for malignant epithelioid mesothelioma (Figs
2A and 2B). Immunohistochemistry showed retained
expression of BAP-1, p16, and MTAP protein, whereas
a CDKN2A fluorescent in situ hybridization (FISH)
analysis revealed no loss of the 9p21 chromosome.
COMPREHENSIVE GENOMIC PROFILING
To identify drug-targetable mutations, CGP using next-
generation sequencing using FoundationOne (Foun-
dation Medicine, Cambridge, MA) was performed
on the exons of 315 cancer-associated genes.12 In
addition, intronic regions of 28 genes that are known
to be involved in somatic rearrangements were
sequenced, and the microsatellite instability and tumor
mutational burden were assessed.13 The sequencing
analysis identified an isolated STRN-ALK rearrange-
ment and three variants of unknown significance,
namely FGFR2 (c.1562A.G, p.D521G), KMT2D
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p.R2069Q). Mutational burden was low (three mutations
per megabase pair), and microsatellites were found to be
stable. Genetic alterations in theNF2 genewere not detected
nor were additional oncogenic drivers known to be present in
malignant mesotheliomas (Fig 3). Subsequently, the STRN-
ALK rearrangement was validated by immunohistochemistry
showing strong protein expression of ALK (clone 5A4;
Fig 4A). A FISH analysis revealed a 5′ ALK deletion in 96% of
the tumor cells (Fig 4B).
TREATMENT AND FOLLOW-UP
After the histologic diagnosis was established, the patient
was initially treated with four cycles of cisplatin and
pemetrexed without clinical or radiologic response. She
was reviewed by a national peritoneal mesothelioma sur-
gical team who staged her laparoscopically and deemed
her case not amenable to cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy. Therefore, pal-
liative care with ascites drainage (6 L/week) was provided.
Molecular testing by CGP was attempted to obtain possible
options for targeted treatment. After the STRN-ALK rear-
rangement was detected, treatment was started with off-label
oral ceritinib 450 mg once per day. Follow-up imaging 6 and
12 weeks after the start of treatment demonstrated a sig-
nificant reduction in the previously observed abdominal
mass and resolution of ascites and hydronephrosis. At
3 months after treatment, there was a further reduction in
the volume of peritoneal disease and ascites (Fig 1). Except
Before treatment 6 weeks of treatment 12 weeks of treatment
FIG 1. Gadolinium-enhanced magnetic resonance imaging scans of the abdomen before and at 6 weeks and
12 weeks after starting ceritinib. Images before treatment demonstrate large-volume ascites, bilateral hydro-
nephrosis, and widespread peritoneal soft tissue deposits particularly within the pelvis (all findings marked by green
arrows). Follow-up imaging 1 month after treatment was started showed a significant reduction in tumor bulk in these
areas and reduction in volume of ascites. Hydronephrosis has resolved. At 12 weeks after treatment, there is a further
reduction in the volume of peritoneal disease and ascites.
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FIG 2. (A) Peritoneal biopsy with a neoplasm showing a tubulopapillary and solid growth pattern (original mag-
nification ×5). (B) Higher magnification (original magnification × 20) shows relatively bland tumor cells with slightly
irregular nuclei and inconspicuous nucleoli. Hematoxylin and eosin stain was used for (A) and (B).
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STRN exon 3 ALK exon 20
TGTACCGCCGG… 
V– –Y– –R– –R–…
…TATGATTCTG 
…–Y– –D– –S– –
14
FIG 3. Next-generation sequencing data showing the STRN-ALK fusion. (A) Alignment of 176 paired-end reads spanning both breakpoints in STRN
and ALK are shown on the human reference genome (hg19). Position of depicted genomic regions are labeled in blue at the top. The breakpoints in
STRN and ALK were found in intron 3 (chr2:37,134,246-37,134,536) and intron 19 (chr2:29,447,483-29,447,805), respectively. (B) Schematic
representation of the STRN-ALK fusion showing the 700-amino-acid (AA)-long fusion gene, with 137 AAs originating from the N terminus of STRN and
the remaining 562 AAs originating from the C terminus of ALK. Although the Striatin domain in the STRN-ALK fusion is likely nonfunctional because of
its premature truncation at its C-terminal region, the tyrosine kinase domain of ALK remains intact.
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for a transient and self-limiting rise in alanine amino-
transferase (ALT), no adverse effects were noted.
DISCUSSION
We report a dramatic tumor regression after the first cycle of
ceritinib in a 13-year-old girl with ALK-rearranged perito-
neal MM. The ALK receptor can be translocated, mutated,
or overexpressed in non-squamous non–small-cell lung
cancer, inflammatory myofibroblastic tumors (IMTs), and
anaplastic large-cell lymphomas (ALCLs).14 It is well known
that pediatric patients with IMTs or ALCL can show strong
and sustained clinical response to the inhibitory effects of
the ALK-targeting drug crizotinib.15 Peritoneal MM is an
extremely rare tumor in children, but an almost complete
response to an ALK-targeting drug has never been de-
scribed before. Recently, Loharamtaweethong et al16
reported a 10-year-old girl with an ALK-translocated
peritoneal MM detected by FISH and immunohistochem-
istry, but the exact fusion partner was not determined. This
patient received combined treatment with cisplatin and
gemcitabine, which resulted in stable disease but not re-
mission. This patient strengthens the importance of access
to specific drugs for rare tumors with rare molecular al-
terations. Rearrangements in the ALK gene have been
identified in a small subset of patients with peritoneal MM
and are thought to be involved in its pathogenesis. Peri-
toneal MM with ALK rearrangements most often occurs in
female patients younger than age 40 years with no history of
asbestos exposure or radiotherapy. Genetic alterations
frequently seen in pleural and peritoneal mesothelioma,
including CDKN2A, BAP-1, NF2, and SETD2, are not
detected in patients with ALK-rearranged disease.11 Even
though the prevalence of ALK-rearranged peritoneal me-
sotheliomas is low, ALK alterations seem to be restricted to
peritoneal mesothelioma only and do not occur in pleural
MM. By using ALK FISH, Salvi et al17 were unable to de-
tect ALK translocations in 106 patients with pleural me-
sothelioma with different histologic subtypes (epithelioid
[n = 60], sarcomatoid [n = 34], and biphasic [n = 12]). This
is consistent with our observation, because we were unable
to demonstrate ALK expression in a tissue microarray
containing tumor samples from 221 patients with pleural
mesothelioma, including 22 females of whom three were
younger than age 40 years (unpublished data).
In our patient’s tumor sample, we identified a rare ALK
fusion by CGP. The platform used in this study can detect
all ALK alterations (including ATG16L1 and TPM1 fusions)
and has been extensively validated.12 Even in ALK FISH-
negative patients, ALK rearrangements could be identified
by using this method.18 In our patient, we detected an
STRN-ALK fusion with similar breakpoints but with a fusion
protein identical to that in the ALK-rearranged patient
described by Hung et al.11 The STRN-ALK fusion was an in-
frame alteration with breakpoints for STRN in intron 3 and
ALK in intron 19.
Patients with ALK-rearranged MM cannot be distinguished
from their conventional counterparts, but the differences
in clinical presentation (young patients with no history
of asbestos exposure) and the detection of isolated ALK
mutations would justify a separate tumor entity of
ALK-rearranged mesothelioma. In the absence of genetic
alterations of CDKN2A, BAP-1, NF2, and SETD2, it is
tempting to speculate that fusions involving the ALK gene
may represent the predominant oncogenic driver in peri-
toneal MM in young female patients. On the basis of the
success of therapeutic ALK inhibition in our patient, ALK
fusion screening by CGP is highly advised in peritoneal
MMs, especially in young patients. The promising response
in our patient also stresses the need for investigations in-
volving a larger cohort of young female patients with ALK-
rearranged peritoneal MM to determine the efficacy and
durability of ALK inhibition. However, such a clinical trial is
difficult to perform, given the rarity of this MM subtype.
Alternative approaches for obtaining the data needed
regarding response to ALK inhibitor therapy in this rare
A B
FIG 4. (A) Immunohistochemical staining showing strong expression of ALK protein (original magnification ×40).
(B) ALK fluorescent in situ hybridization break-apart probes showing one fused red-green signal and one red signal
in 96% of the tumor cells compatible with 5′ ALK deletion (original magnification ×100).
Rüschoff et al
4 © 2019 by American Society of Clinical Oncology
entity could be a search within international cancer
registries, such as the European Platform on Rare
Disease Registration, or inclusion of ALK-rearranged
peritoneal MM into basket trials for variable ALK-
rearranged neoplasia (eg, lung cancer, anaplastic large-cell
lymphoma, and inflammatory myofibroblastic tumors).
Positive response to ALK inhibition in a larger cohort of
patients with peritoneal mesotheliomas would justify
a separate entity of ALK-rearranged MM in a future WHO
classification.
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